(Updated - June 9, 2015 5:49 PM EDT)Esperion Therapeutics ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Trader Talk

Esperion Therapeutics (ESPR) Has Notable New Fan at the FDA and Should Be Bought on Weakness - BarclaysJune 11, 2015 2:21 PM Credit Suisse Defends Esperion Therapeutics (ESPR); Does Not See Impact from PCSK9 PanelJune 10, 2015 1:06 PM Esperion Therapeutics (ESPR) Price Target Lowered to $50 at ChardanJune 10, 2015 10:06 AM Alirocumab AdComm Net Positive for Esperion Therapeutics (ESPR) ETC-1002, Needham & Company SaysJune 10, 2015 8:15 AM Esperion Therapeutics (ESPR) Weakness Overdone Amid FDA AdCom on SNY/REGN's Praluent, UBS SaysJune 10, 2015 7:56 AM RBC Capital Comments on Regeneron (REGN) Following 'Unexpectedly Cautious' AdcomJune 10, 2015 7:09 AM Regeneron (REGN) Resumes Trading Up 1%June 9, 2015 6:50 PM Regeneron (REGN) to Resume Trading at 6:50PM ETJune 9, 2015 6:36 PM Regeneron (REGN) Confirms FDA Panel Backing of PraluentJune 9, 2015 6:34 PM